Exchange: NYSEArca·Updated 07:30 PM EDT
News
all
press releases
ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns
Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study.
Stocktwits
ABVX Stock Rockets 28% After Abivax Eases Drug Safety Concerns With Fresh Clinical Data
Abivax said the findings strengthen the overall case for obefazimod and reinforce its favorable benefit-risk profile.
Stocktwits
ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears
Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers and other malignancies observed in its ulcerative colitis trial.
Stocktwits
ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit Sentiment
The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment.
Stocktwits

Advertisement|Remove ads.